8-K: Moleculin Biotech Announces Positive Clinical Trial Updates and Accelerated Timelines for Annamycin

Moleculin Biotech reports positive progress in its Annamycin clinical trials, including accelerated timelines for Phase 3 data readouts and strong Phase 2 results in AML.

Summary

• Moleculin Biotech has provided a business outlook and outlined expected upcoming milestones for its drug candidate, Annamycin.
• The company received IRB approval for the pivotal Phase 3 MIRACLE trial for Annamycin in combination with cytarabine for relapsed or refractory AML.
• The MIRACLE trial is an adaptive design with an initial 75-90 subjects randomized to different doses of Annamycin and cytarabine.
• Preliminary data from the MIRACLE trial is expected in the second half of 2025 (n=45) and the first half of 2026 (n=~75-90).
• Phase 2 data showed Annamycin plus Ara-C achieved a 60% CR/CRi rate in subjects relapsed from or refractory to Venetoclax, which is more than four times greater than historical rates.
• The company is also advancing Annamycin for soft tissue sarcoma lung metastases, with final data expected in early 2025.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for AML and Orphan Drug Designation for soft tissue sarcoma.
• The company believes Annamycin has the potential to be a game-changing asset for AML treatment and is moving aggressively with its clinical development plan.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strong Phase 2 results, accelerated timelines for Phase 3, and management's confidence in Annamycin's potential. However, the need for significant additional financing introduces some uncertainty.

Positives

• The Phase 3 MIRACLE trial is progressing with IRB approval and is on track to begin dosing in Q1 2025.
• The accelerated timelines for data readouts in the MIRACLE trial are a positive development.
• The 60% CR/CRi rate in Phase 2 for Annamycin plus Ara-C in Venetoclax-resistant AML patients is significantly higher than historical rates.
• The company has received positive feedback from potential investigators regarding recruitment for the MIRACLE trial.
• Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA and EMA, which can expedite the approval process.
• The company is using a leading CRO to conduct the MIRACLE trial.

Negatives

• The company will require significant additional financing to conduct its clinical trials.
• The milestones described in the press release assume the company's ability to secure financing on a timely basis.
• The company is subject to risks and uncertainties, including those discussed in their SEC filings.

Risks

• The company's ability to secure additional financing is critical for the success of its clinical trials.
• The company is subject to regulatory risks, including potential feedback from the FDA and foreign equivalents.
• The clinical trial results may not be as positive as expected.
• The company is subject to risks and uncertainties, including those discussed in their SEC filings.

Future Outlook

The company anticipates achieving value-driving milestones through the next several years, starting with the imminent beginning of enrollment for the MIRACLE trial and the first interim read-out from that study later this year. The company also expects to begin submission of a Rolling New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE in 2028.

Management Comments

• Walter Klemp, Chairman and CEO of Moleculin, stated that the bar for approval is low, and the potential reward for shareholders is substantial.
• Walter Klemp also stated that they have never been more excited about the prospects for Annamycin.

Industry Context

The announcement highlights the potential of Annamycin to address the high unmet need in AML treatment, particularly in patients who have relapsed or are refractory to existing therapies. The positive Phase 2 results and accelerated timelines for the Phase 3 trial position Moleculin as a potential competitor in the AML space.

Comparison to Industry Standards

• The Phase 2 results of Annamycin plus Ara-C achieving a 60% CR/CRi rate in Venetoclax-resistant AML patients is significantly higher than historical rates, suggesting a potential advantage over existing treatments.
• The company states that Annamycin's performance in Phase 2 has outperformed the response rates seen in billion-dollar assets in the AML space, indicating a strong competitive position.
• The median overall survival of 11.6 months for 2nd line subjects in the MB-106 trial is a positive signal compared to typical outcomes in R/R AML.

Stakeholder Impact

• Shareholders may benefit from the potential value creation of Annamycin.
• Patients with AML may have a new treatment option with potentially better outcomes.
• Employees may benefit from the company's growth and success.
• The company's success may impact suppliers and other stakeholders.

Next Steps

• Begin dosing of Annamycin in combination with cytarabine for the treatment of R/R AML in Q1 2025.
• Provide updates on MIRACLE trial site selection/approvals by countries in Q1 2025.
• Provide recruitment updates for the MIRACLE trial throughout 2025.
• Release data readout (n=45) unblinded efficacy/safety review in 2H 2025.
• Release interim efficacy and safety data (n=~75-90) unblinded in 1H 2026.
• Begin enrollment of 3rd line subjects in MIRACLE2 in 2027.
• End enrollment in 2nd line subjects in 2027.
• Release primary efficacy data for 2nd line subjects in MIRACLE in 2028.
• Begin submission of a Rolling New Drug Application (NDA) for the treatment of R/R AML in 2028.

Key Dates

Keywords

Annamycin, AML, Acute Myeloid Leukemia, MIRACLE trial, Phase 3, Clinical Trial, Cytarabine, R/R AML, Soft Tissue Sarcoma, Orphan Drug Designation, Fast Track Status, Venetoclax, MB-106, MB-108, MB-107